Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at The Goldman Sachs Group

The Goldman Sachs Group initiated coverage on shares of Enliven Therapeutics (NASDAQ:ELVN) in a research note released on Monday, MarketBeat.com reports. The firm issued a buy rating and a $37.00 price objective on the stock.

Other analysts have also issued research reports about the stock. Jones Trading reduced their price target on shares of Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating on the stock in a research report on Friday, May 16th. HC Wainwright increased their price target on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, May 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Enliven Therapeutics has an average rating of “Buy” and an average price target of $39.60.

Enliven Therapeutics Trading Up 5.4%

NASDAQ ELVN opened at $23.09 on Monday. The firm has a market capitalization of $1.13 billion, a price-to-earnings ratio of -12.15 and a beta of 0.79. The firm’s 50 day simple moving average is $18.30 and its 200 day simple moving average is $20.60. Enliven Therapeutics has a 1 year low of $13.30 and a 1 year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06). On average, equities research analysts forecast that Enliven Therapeutics will post -1.95 earnings per share for the current year.

Insider Buying and Selling at Enliven Therapeutics

In other news, insider Joseph P. Lyssikatos sold 12,500 shares of Enliven Therapeutics stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $20.61, for a total transaction of $257,625.00. Following the transaction, the insider now owns 1,002,688 shares in the company, valued at approximately $20,665,399.68. The trade was a 1.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction on Monday, April 7th. The stock was sold at an average price of $18.04, for a total transaction of $120,272.68. Following the transaction, the chief operating officer now owns 316,643 shares in the company, valued at approximately $5,712,239.72. This trade represents a 2.06% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 88,611 shares of company stock worth $1,676,289 over the last quarter. Corporate insiders own 25.90% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

A number of hedge funds have recently modified their holdings of ELVN. Polar Capital Holdings Plc lifted its holdings in shares of Enliven Therapeutics by 267.6% during the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock worth $53,768,000 after purchasing an additional 1,739,668 shares during the period. Boxer Capital Management LLC acquired a new position in shares of Enliven Therapeutics during the fourth quarter worth $15,106,000. Janus Henderson Group PLC lifted its holdings in shares of Enliven Therapeutics by 27.9% during the fourth quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company’s stock worth $30,001,000 after purchasing an additional 290,153 shares during the period. FMR LLC lifted its holdings in shares of Enliven Therapeutics by 3.2% during the fourth quarter. FMR LLC now owns 6,495,871 shares of the company’s stock worth $146,157,000 after purchasing an additional 199,692 shares during the period. Finally, Pictet Asset Management Holding SA lifted its holdings in shares of Enliven Therapeutics by 16.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company’s stock worth $21,877,000 after purchasing an additional 135,969 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.